Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.

Koolen BB, van der Leij F, Vogel WV, Rutgers EJ, Vrancken Peeters MJ, Elkhuizen PH, Valdés Olmos RA.

Acta Oncol. 2014 Jan;53(1):50-7. doi: 10.3109/0284186X.2013.783714. Epub 2013 May 14.

PMID:
23672678
2.

Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors.

Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T.

Int J Clin Oncol. 2010 Dec;15(6):588-93. doi: 10.1007/s10147-010-0120-3. Epub 2010 Sep 1.

PMID:
20809217
3.

Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

BMC Cancer. 2008 Jun 9;8:165. doi: 10.1186/1471-2407-8-165.

4.

18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.

Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, Madar O, Cherel P, Pecking AP.

Cancer. 2009 Nov 1;115(21):5038-47. doi: 10.1002/cncr.24534.

5.

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

Jpn J Clin Oncol. 2008 Apr;38(4):250-8. doi: 10.1093/jjco/hyn019.

6.

Breast cancer staging in a single session: whole-body PET/CT mammography.

Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, Kimmig KR, Forsting M, Bockisch A, Antoch G.

J Nucl Med. 2008 Aug;49(8):1215-22. doi: 10.2967/jnumed.108.052050. Epub 2008 Jul 16.

7.
8.

Preoperative PET/CT in early-stage breast cancer.

Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, Tange UB, Andersson M, Kjær A, Loft A, Graff J.

Ann Oncol. 2012 Sep;23(9):2277-82. doi: 10.1093/annonc/mds002. Epub 2012 Feb 21.

9.

Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, Hahn S, Bockisch A, Lauenstein T, Antoch G, Heusner TA.

Eur J Nucl Med Mol Imaging. 2012 May;39(5):852-63. doi: 10.1007/s00259-012-2077-0. Epub 2012 Mar 6.

PMID:
22392069
10.

Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.

García Vicente AM, Soriano Castrejón A, Cruz Mora MÁ, Ortega Ruiperez C, Espinosa Aunión R, León Martín A, González Ageitos A, Van Gómez López O.

Rev Esp Med Nucl Imagen Mol. 2014 Jan-Feb;33(1):1-5. doi: 10.1016/j.remn.2013.03.005. Epub 2013 May 23.

11.

Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.

Agresti R, Crippa F, Sandri M, Martelli G, Tagliabue E, Alessi A, Pellitteri C, Maccauro M, Maugeri I, Barbara P, Rampa M, Moscaroli A, Ferraris C, Carcangiu ML, Bianchi G, Greco M, Bombardieri E.

Breast. 2014 Aug;23(4):334-40. doi: 10.1016/j.breast.2014.01.001. Epub 2014 Jan 31.

PMID:
24485802
12.

Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.

Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, Fontanillas M, Pons F.

J Clin Oncol. 2008 Oct 10;26(29):4746-51. doi: 10.1200/JCO.2008.17.1496. Epub 2008 Aug 11.

13.

Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.

Crippa F, Agresti R, Seregni E, Greco M, Pascali C, Bogni A, Chiesa C, De Sanctis V, Delledonne V, Salvadori B, Leutner M, Bombardieri E.

J Nucl Med. 1998 Jan;39(1):4-8.

14.

Preoperative FDG-PET for axillary metastases in patients with breast cancer.

Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hagiike M, Phillips EH.

Arch Surg. 2006 Aug;141(8):783-8; discussion 788-9.

PMID:
16924086
15.

Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.

Riegger C, Koeninger A, Hartung V, Otterbach F, Kimmig R, Forsting M, Bockisch A, Antoch G, Heusner TA.

Acta Radiol. 2012 Dec 1;53(10):1092-8. doi: 10.1258/ar.2012.110635. Epub 2012 Sep 22.

PMID:
23002144
16.

[Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].

Zhao TT, Li JG, Li YM.

Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):206-9. Chinese.

PMID:
17649638
17.

Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.

García García-Esquinas MA, Arrazola García J, García-Sáenz JA, Furió-Bacete V, Fuentes Ferrer ME, Ortega Candil A, Cabrera Martín MN, Carreras Delgado JL.

Rev Esp Med Nucl Imagen Mol. 2014 Jan-Feb;33(1):14-21. doi: 10.1016/j.remn.2013.04.008. Epub 2013 Jul 1.

18.

Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.

Seo MJ, Lee JJ, Kim HO, Chae SY, Park SH, Ryu JS, Ahn SH, Lee JW, Son BH, Gong GY, Moon DH.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):438-45. doi: 10.1007/s00259-013-2600-y. Epub 2013 Nov 6.

PMID:
24196918
19.

Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.

Koolen BB, Valdés Olmos RA, Elkhuizen PH, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ.

Breast Cancer Res Treat. 2012 Aug;135(1):231-40. doi: 10.1007/s10549-012-2179-1. Epub 2012 Jul 28.

PMID:
22872522
20.

Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.

Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA.

J Nucl Med. 2015 Nov;56(11):1674-80. doi: 10.2967/jnumed.115.161455. Epub 2015 Aug 20.

Items per page

Supplemental Content

Write to the Help Desk